ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in I-Mab with Losses of $100,000 to Contact the FirmNewsfile Corp • 09/02/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMABNewsfile Corp • 09/01/22
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022PRNewsWire • 08/30/22
I-Mab to Report Business and Corporate Updates and Financial Results for the Six Months Ended June 30, 2022 on August 30, 2022PRNewsWire • 08/19/22
I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1BB Bispecific Antibody TJ-CD4B in Solid Tumors in ChinaPRNewsWire • 07/22/22
I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022PRNewsWire • 07/18/22
I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210PRNewsWire • 06/15/22
Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)Business Wire • 06/14/22
I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone DeficiencyPRNewsWire • 05/31/22
I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody UliledlimabPRNewsWire • 05/26/22
I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody UliledlimabPRNewsWire • 05/19/22
I-Mab Provides Updates on Status under Holding Foreign Companies Accountable ActPRNewsWire • 05/05/22
I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical OfficerPRNewsWire • 04/28/22
I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term CommitmentPRNewsWire • 03/31/22
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021PRNewsWire • 03/29/22
I-Mab to Report Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022PRNewsWire • 03/18/22